Target Software has entered into a licensing and services agreement to implement and operate the Target SFA sales effectiveness suite for OSI Pharmaceuticals Inc.'s Oncology business, a company release said.
The Target SFA suite will become OSI's central sales information management solution and the Target Software Support Center will provide training, hosting, help desk, data management and other SFA operational services for OSI on an ongoing basis.
OSI's national sales force is being deployed on Target Mobile, Target Software's ultra-portable mobile sales software. OSI oncology sales specialists will manage their daily activities using the advanced account-based selling features of Target Mobile. Account profiling, affiliation management, route planning, event management and sales data presentation functions will all be used to enhance sales specialist and overall sales force effectiveness. OSI regional managers will utilize Target Software's web-based transaction monitoring and reporting tools.
Target BackOffice will become part of OSI Pharmaceutical's central sales data warehouse and CRM solution. Target Software's data pipeline technology, TIM, will be used to integrate a continuous stream of specially-prepared third-party marketing and segmentation data to help the OSI sales specialists more effectively target Healthcare Professionals in the Oncology market.
"However, we also provide many streamlined features that make our software equally attractive for account-focused companies like OSI. Our account-based selling technology provides specialized functions that are sorely needed by specialty pharmaceutical sales organizations of all sizes," said Ted Rosenberger, Target Software's chairman and CEO.
Target Software is a provider of mobile sales force automation, sample control and account-based selling solutions for the pharmaceutical industry. Target Software's clients include Ventiv Health, Merz Pharmaceuticals, Pamlab, Mission Pharmacal, OSI Pharmaceuticals, Publicis Selling Solutions, Phoenix Marketing Group, Aventis and Wyeth.
OSI Pharmaceuticals focuses on the development and commercialization of oncology products for cancer patients worldwide.